Oxidative polymorphism of dextromethorphan in a Burundi population.
The wide availability, metabolism by the same cytochrome P450 as debrisoquine and, above all, the inocuity of dextromethorphan (DMP) favour the frequent choice of this drug as the test substance in determining oxidation phenotypes. 100 healthy Burundian volunteers (94 m and 6 f) in this study ingested 50 mg DMP bromhydrate, i.e. 38.5 mg of DMP base. Urine was collected for 8 h following the dose and TLC was used to analyse it. The method was particularly useful in view of its low cost, speed and the ease of applying it to a large study group. 5% of the Burundian subjects were poor metabolizers.
Nsabiyumva
F
F
Central Hospital University of Bujumbura, Burundi.
Furet
Y
Y
Autret
E
E
Jonville
A P
AP
Breteau
M
M
D000328:Adult; D002063:Burundi; D003915:Dextromethorphan / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic
D003915:Dextromethorphan